Posted by Michael Wonder on 05 Jan 2024
ProfoundBio announces rinatabart sesutecan FDA fast track designation for patients with advanced ovarian cancer
5 January 2023 - ProfoundBio today announced that the US FDA has granted fast track designation for rinatabart sesutecan (Rina-S; PRO1184), a folate receptor alfa targeted antibody drug conjugate, for the treatment of patients with FRα expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.
Rina-S is a folate receptor alfa targeted antibody drug conjugate being developed as a novel treatment option for patients with ovarian and endometrial cancer, and potentially other FRα expressing cancers.
